{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:00:16Z","timestamp":1792605616113,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.cgh.2018.02.024","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T20:05:55Z","timestamp":1519934755000},"page":"1374-1384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7980-9368","authenticated-orcid":false,"given":"Robert P.","family":"Hirten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Iacucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-9959","authenticated-orcid":false,"given":"Shailja","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrata","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Frederic","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2018.02.024_bib1","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","article-title":"Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: a meta-analysis","volume":"22","author":"Reinink","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/2050640615590302","article-title":"Biologics in inflammatory bowel disease: What are the data?","volume":"3","author":"Cote-Daigneault","year":"2015","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2018.02.024_bib3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.02.024_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.02.024_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.02.024_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib7","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.02.024_bib8","doi-asserted-by":"crossref","first-page":"e000127","DOI":"10.1136\/bmjgast-2016-000127","article-title":"Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis","volume":"4","author":"Bethge","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2018.02.024_bib9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.02.024_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.cgh.2018.02.024_bib12","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib13","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-alpha and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib14","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1016\/j.jaad.2005.10.032","article-title":"Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis","volume":"54","author":"Papp","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2230.2007.02673.x","article-title":"When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents","volume":"33","author":"Adisen","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5070\/D31HD646HW","article-title":"A\u00a0case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis","volume":"15","author":"Kitamura","year":"2009","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.cgh.2018.02.024_bib17","first-page":"1089","article-title":"Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy","volume":"7","author":"Hamilton","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.det.2004.03.014","article-title":"Current concepts and review of alefacept in the treatment of psoriasis","volume":"22","author":"Krueger","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.cgh.2018.02.024_bib19","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaad.2005.08.032","article-title":"Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept","volume":"54","author":"Krell","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib20","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2018.02.024_bib21","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/rheumatology\/kel211","article-title":"Effective co-administration of infliximab and etanercept following the failure of sequential anti-TNF agents in a patient with HLA-b27-associated arthropathy","volume":"45","author":"Sheehy","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2018.02.024_bib22","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2018.02.024_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/keh483","article-title":"Anti-TNF-alpha therapies: they are all the same (aren't they?)","volume":"44","author":"Mpofu","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2018.02.024_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10141","article-title":"Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"Cohen","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib27","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1073\/pnas.88.10.4181","article-title":"Reshaping a therapeutic CD4 antibody","volume":"88","author":"Gorman","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2018.02.024_bib28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/qjmed\/hcn006","article-title":"A\u00a0pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis","volume":"101","author":"Morgan","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.cgh.2018.02.024_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib30","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib32","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3899\/jrheum.090160","article-title":"Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents","volume":"36","author":"Koumakis","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/1874312900903010009","article-title":"Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: Case report","volume":"3","author":"Feuchtenberger","year":"2009","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.cgh.2018.02.024_bib34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/rheumatology\/ken491","article-title":"Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis","volume":"48","author":"Blank","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2018.02.024_bib35","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib36","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3899\/jrheum.120924","article-title":"Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study","volume":"40","author":"Rigby","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib37","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib38","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/art.39262","article-title":"Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled pilot trial","volume":"67","author":"van Vollenhoven","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib39","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","article-title":"Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study","volume":"54","author":"Weinblatt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2018.02.024_bib40","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3899\/jrheum.100726","article-title":"Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series","volume":"38","author":"Record","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.cgh.2018.02.024_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000342842","article-title":"Combined infliximab and rituximab in necrotising scleritis","volume":"3","author":"Morarji","year":"2012","journal-title":"Case Rep Ophthalmol"},{"key":"10.1016\/j.cgh.2018.02.024_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ajg.2015.207","article-title":"Health insurance paid costs and drivers of costs for patients with Crohn\u2019s disease in the united states","volume":"111","author":"Park","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2018.02.024_bib43","doi-asserted-by":"crossref","first-page":"e0185500","DOI":"10.1371\/journal.pone.0185500","article-title":"A\u00a0systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease","volume":"12","author":"Pillai","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2018.02.024_bib44","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1097\/MIB.0b013e3182916046","article-title":"A\u00a0systematic review of economic studies on biological agents used to treat Crohn\u2019s disease","volume":"19","author":"Tang","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2018.02.024_bib45","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s10198-012-0430-7","article-title":"Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn\u2019s disease","volume":"14","author":"Marchetti","year":"2013","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.cgh.2018.02.024_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2036.2008.03709.x","article-title":"Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn\u2019s disease\u2013modelling outcomes in active luminal and fistulizing disease in adults","volume":"28","author":"Lindsay","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2018.02.024_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","article-title":"Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data","volume":"30","author":"Bodger","year":"2009","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518301691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356518301691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:24:43Z","timestamp":1761542683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356518301691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":47,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1542356518301691"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2018.02.024","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2018.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the AGA Institute","name":"copyright","label":"Copyright"}]}}